Manufacturer of Controlled Substances; Notice of Registration, 4054 [E9-1196]
Download as PDF
4054
Federal Register / Vol. 74, No. 13 / Thursday, January 22, 2009 / Notices
$16.00 (25 cents per page reproduction
cost) payable to the U.S. Treasury or, if
by e-mail or fax, forward a check in that
amount to the Consent Decree Library at
the stated address.
Ronald Gluck,
Assistant Chief, Environmental Enforcement
Section, Environment and Natural Resources
Division.
[FR Doc. E9–1155 Filed 1–21–09; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
rmajette on PRODPC74 with NOTICES
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on
September 18, 2008, ISP Freetown Fine
Chemicals, 238 South Main Street,
Assonet, Massachusetts 02702, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
Phenylacetone to manufacture
Amphetamine.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 23, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
VerDate Nov<24>2008
14:47 Jan 21, 2009
Jkt 217001
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: January 14, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–1198 Filed 1–21–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated October 9, 2008 and
published in the Federal Register on
October 17, 2008 (73 FR 61909),
Noramco Inc., Division of Ortho McNeil,
Inc., 500 Swedes Landing Road,
Wilmington, Delaware 19801–4417,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Schedule
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Morphine-N-oxide (9307) .............
Methylphenidate (1724) ................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Oxymorphone (9652) ...................
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to bulk
manufacture the above listed controlled
substances for sale and distribution to
manufacturers for product development
and formulation.
Drug code 1726 (methylphenidate)
has been withdrawn from the
application for registration as all
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
manufacturing activity for
methylphenidate can be conducted
under drug code 1724 for the same
substance.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Noramco Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated
Noramco Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 14, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–1196 Filed 1–21–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated September 8, 2008,
and published in the Federal Register
on September 15, 2008 (73 FR 53280),
Chattem Chemicals Inc., 3801 St. Elmo
Avenue, Building 18, Chattanooga,
Tennessee 37409, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedules I and II:
Drug
4-Methoxyamphetamine (7411) ...
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
E:\FR\FM\22JAN1.SGM
22JAN1
Schedule
I
I
I
II
II
II
II
II
II
II
II
II
II
II
Agencies
[Federal Register Volume 74, Number 13 (Thursday, January 22, 2009)]
[Notices]
[Page 4054]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-1196]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated October 9, 2008 and published in the Federal
Register on October 17, 2008 (73 FR 61909), Noramco Inc., Division of
Ortho McNeil, Inc., 500 Swedes Landing Road, Wilmington, Delaware
19801-4417, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053)..................... I
Dihydromorphine (9145)..................... I
Morphine-N-oxide (9307).................... I
Methylphenidate (1724)..................... II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Opium extracts (9610)...................... II
Opium fluid extract (9620)................. II
Opium tincture (9630)...................... II
Opium, powdered (9639)..................... II
Opium, granulated (9640)................... II
Oxymorphone (9652)......................... II
------------------------------------------------------------------------
The company plans to bulk manufacture the above listed controlled
substances for sale and distribution to manufacturers for product
development and formulation.
Drug code 1726 (methylphenidate) has been withdrawn from the
application for registration as all manufacturing activity for
methylphenidate can be conducted under drug code 1724 for the same
substance.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Noramco Inc. to manufacture the listed basic classes of controlled
substances is consistent with the public interest at this time. DEA has
investigated Noramco Inc. to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above
named company is granted registration as a bulk manufacturer of the
basic classes of controlled substances listed.
Dated: January 14, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-1196 Filed 1-21-09; 8:45 am]
BILLING CODE 4410-09-P